A multicentref trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: near final height analysis

D I Johnston, P Betts, D Dunger, N Barnes, P G F Swift, J M H Buckler, G E Butler

Abstract

Background—Turner syndrome accounts for 15–20% of childhood usage of growth hormone (GH) in the UK but final height benefit remains uncertain. The most effective strategy for oestrogen replacement is also unclear.

Methods—Fifty eight girls who, at start of treatment, were of mean age 9.1 years and projected final height 142.2 cm were randomised to receive in year 1, either low dose ethinyloestradiol 50–75 ng/kg/day, GH 28 IU/m2 surface area/week as a daily injection, or a combination of ethinyloestradiol and GH. After the first year, the ethinyloestradiol treated girls received combination treatment. After two years, girls aged over 12 years were given escalating ethinyloestradiol to promote pubertal development.

Results—Near final height was available for 49 girls at age 16.5 years, 146.8 cm, representing a gain of 4.6 cm, range −7.9 to +11.7 cm. Twelve of the 49 girls gaining 7.5 cm or more were less than 13 years at the start and had received GH for at least four years. Height gain was correlated with greater initial height deficit. Fifteen girls (31%) reached 150 cm or more compared to a predicted 10%. Early supplementation with ethinyloestradiol provided no final height advantage.

Conclusions—Final height gain was modest at 4.6 cm. Younger, shorter girls gained greatest height advantage from GH. Low dosage ethinyloestradiol before planned induction of puberty was not beneficial. (Arch Dis Child 2001;84:76–81)

Keywords: Turner syndrome; growth hormone; oestrogen; final height

Short stature is an important issue for most girls with Turner syndrome (TS) but the impact of growth hormone (GH) treatment on childhood growth and final height is uncertain. The availability of recombinant GH in the mid 1980s coincided with preliminary data supporting height gain in girls with Turner syndrome treated with supraphysiological doses of GH. The UK and other countries the product licence for GH was extended to include the treatment of TS despite lack of long term studies to confirm worthwhile advantage for final height. Other unresolved questions include the optimal age range for intervention with GH and potential adverse events. Parallel concerns include the cost to health services, and the impact of daily injections on girls who already carry an increased burden of emotional difficulties.

The additive effect of combined treatment with low dose anabolic agents or oestrogens also requires clarification. Short term experimental studies have suggested a bimodal effect of oestrogens on linear growth; very low dose oestrogen accelerates limb length growth, whereas higher dosage consistent with sexual maturation has a growth suppressing effect.

This study was designed to test two main proposals. First, that sustained treatment with GH in the recommended dose range 28–30 IU/m2/week would result in worthwhile gain to adult height; and second, that low dose ethinyloestradiol given to girls before intended induction of puberty would have an additional growth enhancing effect.

Patients and methods

Fifty eight girls with karyotypes consistent with Turner syndrome were enrolled. Clinical and investigative review had excluded other growth limiting disorders, and none had received prior hormone therapy.

At entry the mean chronological age was 9.1 years (range 5.0–15.4); the girls closely matched the pooled European Turner syndrome height for age standards, the mean height standard deviation score being −0.1 (SD 0.9). Ethical approval was given in the six centres involved, and written consent was obtained.

TREATMENT PROTOCOUL

Following a minimum of six months baseline observation the girls were randomised to one of three first year treatment groups:

1. Low dose oestrogen alone: ethinyloestradiol 1.0 µg/day for age less than 10 years and 2.0 µg/day for age over 10 years (approximating to 50–75 ng/kg body weight daily)

2. Recombinant growth hormone (Genotropin, Pharmacia and Upjohn, Stockholm, Sweden) 28–30 IU/m2 surface area/wk divided as a daily subcutaneous injection

3. Combined ethinyloestradiol and GH

At the end of the first year, group 1 patients were changed to combined ethinyloestradiol and GH treatment. Treatment centres had the option of stopping ethinyloestradiol therapy if girls showed unacceptable premature breast development or excessive bone age maturation.

From age 12 years girls were started on an escalating programme of oestrogen replacement starting with ethinyloestradiol 2.0 µg/day...
for 12 months, 5.0 µg/day for 12 months, and 10 µg/day for 12 months with addition of norethisterone on a cyclical basis. The rate of further oestrogen dose increment was guided by staging of breast development and ultrasound evidence of uterine growth.

The treatment intention was to continue growth hormone treatment until height increase had fallen below 1 cm/year.

PATIENT MONITORING
Standing height, sitting height, and weight were measured at three to six monthly intervals. Height standard deviation scores (HSDS) were derived from published Turner height standards:

\[
\text{HSDS} = \frac{\text{observed height} - \text{Turner height mean for age}}{\text{SD}}
\]

The HSDS at start of treatment was used to derive predicted final height on the assumption that girls with TS have close relations between height in the first decade and adult height. According to this Lyon height projection model, a girl with a starting HSDS of −0.1 would be expected to have a final HSDS of −0.1. The historical mean final height, 143 cm, is derived from TS young women at age 20 years.

Near final height was defined as the height achieved at the end of a 12 month observation period during which height gain had been less than 1.0 cm. Parental HSDS values were calculated using normal population data.

Bone age (BA), initially determined at yearly intervals, was calculated using the Tanner–Whitehouse RUS (radius, ulna and finger (or short) bones) method applicable to a normal female population. Pubertal staging was performed using Tanner–Whitehouse standards.

The following laboratory investigations were performed before entry and annually: full blood count; fasting blood sugar, triglycerides, and cholesterol; HbA1c; electrolytes, creatinine, liver function tests, free thyroxine, thyroid stimulating hormone, luteinising hormone, and follicle stimulating hormone. GH provocation tests were performed prior to entry; peak GH responses were reported but did not qualify patients for entry to this study.

STATISTICAL ANALYSIS
Results are expressed as mean/median (range) or mean (SD). Within group results were compared using the paired Student’s t test. Between group results were compared using analysis of variance. Simple and multiple regression analysis was performed on variables likely to influence final height and gain in height.

### Results
Fifty eight girls entered the study at mean chronological age 9.1 (2.8) years, and with heights matching published Turner standards, mean HSDS −0.1 (0.9) (fig 1). This value matched the mean parental HSDS of −0.1 (1.0) using normal population standards. Table 1 presents the characteristics of girls within the three treatment groups. The groups were similar for the main monitoring parameters.

All three groups showed a significant change in HSDS during the first year: group 1, +0.4 (0.9); group 2, +0.7 (0.7); and group 3, +1.0 (0.9). The changes in groups 2 and 3 were significantly greater than in group 1 (p < 0.05). All groups sustained further increase in HSDS until the end of year 5 after which mean values in reducing numbers of girls levelled off:

### Table 1 Baseline data

<table>
<thead>
<tr>
<th></th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>ANOVA analysis between groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>First year treatment</td>
<td>EO</td>
<td>GH</td>
<td>GH&amp;EO</td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>13</td>
<td>22</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>9.1 (6.0 to 13.7)</td>
<td>9.0 (5.2 to 15.4)</td>
<td>9.1 (5.0 to 14.7)</td>
<td>NS</td>
</tr>
<tr>
<td>Bone age (y)</td>
<td>7.9 (3.0 to 13.7)</td>
<td>8.0 (3.3 to 13.5)</td>
<td>8.1 (3.0 to 12.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>114.0 (94.6 to 140.0)</td>
<td>113.2 (93.2 to 135.1)</td>
<td>114.9 (93.6 to 139.2)</td>
<td>NS</td>
</tr>
<tr>
<td>HSDS for CA</td>
<td>−0.1 (−1.5 to +1.8)</td>
<td>−0.3 (−2.1 to +1.2)</td>
<td>0.1 (−2.2 to +1.8)</td>
<td>NS</td>
</tr>
<tr>
<td>HSDS for BA</td>
<td>1.0 (−0.6 to +2.4)</td>
<td>0.6 (−0.8 to +3.3)</td>
<td>0.8 (−1.6 to +3.7)</td>
<td>NS</td>
</tr>
<tr>
<td>GH peak (mIU/l)</td>
<td>27.8 (9.5 to 44.0)</td>
<td>27.0 (7.9 to 81.0)</td>
<td>22.3 (2.8 to 60.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Mid parental HSDS</td>
<td>−0.3 (1.1)</td>
<td>−0.2 (0.8)</td>
<td>0.7 (1.1)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Results expressed as mean (range) or (SD).

*Oestrogen introduced after age 12 years.

EO, ethinyloestradiol; GH, growth hormone; GH&EO, combined treatment; CA, chronological age; BA, bone age; HSDS, height standard deviation score; NS, not significant.

www.archdischild.com
events not directly related to GH or ethinyloestradiol: one patient each with hypertension, ulcerative colitis, and brain tumour. One patient in group 3, aged 15.8 years, died from aortic dissection shortly after cessation of growth hormone treatment, having reached near final height. Compliance problems led to the withdrawal of four patients. Seven other girls developed coincidental disorders, notably thyroiditis requiring thyroxine treatment, but these were not considered sufficient to invalidate continued participation in the study.

Five girls allocated to early ethinyloestradiol were converted to GH alone because of concern over early breast development at age range 6.2–8.9 years, or because of relative bone age advance. Oestrogen was withdrawn in one girl aged 11.7 years who subsequently sustained partial spontaneous pubertal change without exogenous oestrogen. Final height data are not available for two girls.

Near final height as judged by height velocity less than 1 cm/year and cessation of GH therapy are available for 49 girls at age 16.5 (1.34) years (range 13.6–19.8). In the absence of an effect of first year treatment on final height, the results of the whole group have been analysed together. Mean duration of GH treatment was 5.6 (2.2) years (range 1–10).

The mean near final height was 146.8 (4.9) cm (range 136.6–155.3). In comparison with TS height standards for a mean age of 16.5 years, the age at which near final heights were reached, the apparent mean height gain was 8.8 (5.6) cm, matching an HSDS increase of 1.3 (0.8). However, historical final height standards are based on TS young women aged 20 years and adjustment for this final height standard reduced mean height gain to 4.6 (4.5) cm (range −7.9 to +11.7). By comparison with heights predicted for age 20 years, 18 of 49 girls had height gain 5 cm or more, and 12 had a gain 7.5 cm or more. Of girls gaining 7.5 cm or more, none were older than 13 years at start of treatment, and all received a minimum of four years of GH.

Using the arbitrary height of 150 cm as a threshold for “normal stature”, 15 of 49 girls (31%) achieved this target compared with an initially predicted five (10%).

Table 2  Final height data

<table>
<thead>
<tr>
<th></th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>ANOVA analysis between groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start number</td>
<td>13</td>
<td>22</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Final number</td>
<td>12</td>
<td>17</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Study duration (y)</td>
<td>6.6</td>
<td>5.3</td>
<td>5.1</td>
<td>NS</td>
</tr>
<tr>
<td>GH duration (y)</td>
<td>5.6 (2.5)</td>
<td>5.3 (2.1)</td>
<td>5.1 (1.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Range</td>
<td>(2 to 9)</td>
<td>(1 to 10)</td>
<td>(1 to 7.3)</td>
<td></td>
</tr>
<tr>
<td>Age at near final height (y)</td>
<td>16.7 (1.4)</td>
<td>16.3 (1.4)</td>
<td>16.4 (1.3)</td>
<td>NS</td>
</tr>
<tr>
<td>Range</td>
<td>(14.6 to 19.8)</td>
<td>(14.5 to 19.2)</td>
<td>(13.6 to 19.3)</td>
<td></td>
</tr>
<tr>
<td>Near final height (cm)</td>
<td>145.5 (4.6)</td>
<td>146.2 (5.3)</td>
<td>148.2 (4.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Range</td>
<td>(138.0 to 152.3)</td>
<td>(137.1 to 155.3)</td>
<td>(136.6 to 155.2)</td>
<td></td>
</tr>
<tr>
<td>Predicted final height (cm)*</td>
<td>142.3 (6.0)</td>
<td>141.3 (5.1)</td>
<td>143.5 (6.9)</td>
<td>1&lt;3</td>
</tr>
<tr>
<td>Range</td>
<td>(133.0 to 155.1)</td>
<td>(128.9 to 151.0)</td>
<td>(128.3 to 155.1)</td>
<td></td>
</tr>
<tr>
<td>Height gain (cm) compared to predicted final height</td>
<td>3.2 (3.8)</td>
<td>4.9 (4.9)</td>
<td>4.7 (4.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Range</td>
<td>(−3.7 to +9.6)</td>
<td>(−7.9 to +11.7)</td>
<td>(−3.8 to +11.4)</td>
<td></td>
</tr>
</tbody>
</table>

Results expressed as mean (SD).
*Derived from age 20 historical standards.
NS, not significant. Probability values refer to intragroup comparison.

Figure 2  Heights at end of study, plotted on Turner standard charts derived from the data of Lyon, Preece, and Grant (1985) compared to UK normal reference (1990). The solid curves represent 3rd, 50th, and 97th centiles for Turner girls. The broken curves represent 0.4th, 50th, and 99.6th centiles for normal girls.

1, +1.2 (0.7); group 2, +1.6 (0.9); and group 3, + 1.8 (0.9); there was no significant difference between groups (see table 2 and fig 2).

At the start, the apparent mean bone age delays were 1.2, 1.0, and 1.0 years for groups 1, 2, and 3 respectively. Groups 1 and 3 initially had more rapid catch up in bone age, but by four years of treatment all three groups had bone age matching chronological age.

The mean (range) age at which Tanner stage 2 breast development (B2) was detected occurred earlier in groups 1 and 3 receiving early ethinyloestradiol (11.7 (8.6–13.6) years and 11.3 (6.8–13.5) years respectively), compared to group 2 (12.5 (10.6–14.5) years) although this difference was not statistically significant. For the total study population the median age at B2 was 12.4 years.

FOLLOW UP DATA

Three of 58 girls ceased growth hormone treatment early because of serious health concerns.

Table 2  Final height data

www.archdischild.com

Johnston, Betts, Danger, Barnes, Swift, Buckler, Butler
Analyses were performed to establish the influence of start chronological age, start BA, start HSDS, midparental HSDS, first year treatment, height response in year 1, relative BA advance, age at B2, and duration of GH treatment on final height and height gain.

Final height was significantly correlated with better initial HSDS ($r = 0.5, p = 0.0001$) and taller parents, midparental HSDS ($r = 0.3, p = 0.0001$). First year treatment allocation did not influence final height.

Height gain over predicted final height for age 20 years was correlated with lower initial chronological age ($r = 0.44, p = 0.001$) and BA ($r = 0.52, p = 0.0001$) as well as shorter stature at onset, HSDS ($r = 0.59, p = 0.0001$). Height gain was also related to first year height response ($r = 0.55, p = 0.0001$) and longer duration of GH treatment ($r = 0.6, p = 0.0001$). First year treatment and age of B2 did not influence final height gain.

**Discussion**

Despite an extensive literature describing the use of GH in girls with TS, it remains uncertain whether current treatment recommendations achieve worthwhile height advantage. Initial studies showing medium term rather than final height advantage convinced many clinicians to embark on a policy of offering GH therapy, and not surprisingly this opportunity for increased stature has been enthusiastically promoted by family support groups. One consequence is that there is limited access to final height data on contemporary groups of girls not given GH, but treated with current oestrogen replacement regimens. It is also likely that the TS population has shown a secular trend to taller stature. In the absence of such comparison data, the majority of studies, including this one, have used historical standards. The pretreatment heights of our study group closely matched historical standards, but we have had to assume that final height standards are also appropriate, and that it is valid to make comparisons between actual final heights achieved and predicted heights derived using these standards.

We have used a relatively strict definition of near final height, a height gain of less than 1.0 cm over the previous 12 months. The mean age of reaching near static growth was 16.5 years. A number of other studies have reported height gain caused by GH as the difference between actual and predicted height at the age at which near final height was reached. A more demanding analysis for assessing the benefit of GH intervention is to compare near final height with predicted height had the untreated girl gone on growing until age 20 years. The latter recognises that TS girls in the era before GH treatment had a slow prolonged growth curve that reached a plateau after age 18 years. It would be inappropriate to attribute presumed height advantage at age 16.5 years to GH intervention if, without treatment, the girl might have had the compensation of an additional two years of slow growth. However, it can also be argued that the contemporary strategy of advising earlier oestrogen replacement, in order to avoid conspicuously delayed puberty, renders the shape of the historical TS growth curve invalid. In other words TS girls treated with oestrogen replacement regimens starting at age 12 to 14 years are likely to have accelerated epiphyseal fusion and reach final height before age 18 years. The current approach of offering oestrogen induced puberty at an age that matches normal peers may lead to a decrease in the late phase of height growth.7

The mean near final height advantage in this study was approximately 8 cm when using height prediction for age 16.5 years, but was reduced to 4.6 cm by comparison with age 20 years standards.

The calculation of predicted final height based on pretreatment height measurements is also a contentious issue. Shah et al have discussed the application of height prediction methods in the context of a large UK retrospective study of GH treated Turner girls."
has provided a challenge for other treatment programmes to emulate. The early recognition of TS girls and prompt referral to centres participating in trials of GH treatment is a key factor in the effectiveness of treatment programmes. International comparisons must also take account of the greater median adult height of North European TS girls, 146.9 cm compared to the historical UK value, 143 cm. It is disappointing that reported UK studies have failed to match the Dutch and US final height gains; potential explanations being later age of recruitment, less successful oestrogen replacement regimens, and unrecognised compliance problems. There is obvious scope for dealing with these potential restraints on final height outcome before embarking on treatment regimens incorporating even higher dose GH or additional anabolic agents. Available safety data on the international use of GH is reassuring, but there is concern regarding the long term metabolic implications of GH treatment induced hyperinsulinism, especially if very high dose GH regimens are used.

It is evident that early age of TS recognition permits longer GH treatment and more effective height normalisation. Further work is required to define other characteristics of TS girls likely to benefit from GH therapy. Height gain with GH treatment is greater for shorter girls but is not demonstrably related to phenotypic features or to whether X chromosome microsatellite markers denote maternal or paternal origin. A heavier weight for height also correlates with GH treatment response. The use of low dose oestrogen prior to the planned induction of puberty was not beneficial for final height, and raised concerns about early breast development and faster skeletal maturation. Other studies have confirmed the relation between early oestrogen exposure and poorer height gain with GH treatment. A recent study, comparing the introduction of oestrogen at age 12 or 15 years, showed that duration of GH therapy before introduction of oestrogen is a predictor of final height, and that it is preferable in terms of height gain for oestrogen induction of puberty to be delayed. The Dutch experience is that low dose oestrogens can be started at a normal pubertal age without interference in the near normalisation of adult height by long term GH. Understanding of the role of oestrogen and GH in bone mineralisation in TS remains speculative, and insufficient to promote early use of oestrogen.

CONCLUSION

This study used the recommended GH dose of 28–30 IU/m²/week administered as a daily injection has confirmed that Turner girls show initial and medium term growth acceleration. Improved growth during early childhood and early adolescence may have a positive impact on patient and family attitude to stature and contribute to enhanced self esteem. The near final height outcomes are improved for the majority of girls, but a realistic appraisal of potential adult height suggests modest benefit.

There is however a sizeable subgroup of TS girls who benefit from achieving adult height in the lower normal range and the criteria that identify these girls more likely to benefit from GH treatment need to be defined. The introduction of low dosage oestrogen before the use of puberty promoting dosage was not advantageous and may have curtailed final height benefit. There is a clear need to conduct further studies to define the optimal use of GH treatment and oestrogen replacement in girls with TS.

This study received financial and organisational support from Pharmacia Upjohn. DJJ was the study convener and main author; PB and DD also participated in the production of this report. All listed authors (except GEH) were responsible for generating the study design and recruiting patients. GEH replaced JMHB following the latter’s retirement from clinical practice.

Ibuprofen for closure of patent ductus arteriosus

Ibuprofen may have advantages over indomethacin for closure of a patent ductus arteriosus (PDA). Although both drugs inhibit both cyclooxygenase I (COX I) and cyclooxygenase II (COX II), ibuprofen is a less potent inhibitor of COX I and, possibly for that and other reasons, has less effect on cerebral, mesenteric, and renal blood flow. In the Fetal & Neonatal edition of this journal (1997;76:F179–84), researchers in Belgium reported on a randomised trial involving 40 preterm infants in which ibuprofen was as effective as indomethacin but had less effect on renal function. They have now extended their observations in a larger series (Bart Van Overmeire and colleagues. New England Journal of Medicine 2000;343:674–81; see also editorial, Ibid:728–9).

A total of 148 babies (gestational ages 24–32 weeks) with respiratory distress syndrome and PDA were randomly assigned at age 2–4 days to three intravenous doses of either indomethacin (0.2 mg/kg 12 hourly) or ibuprofen (10 mg/kg first dose, then 5 mg/kg at intervals of 24 hours). Ductal closure occurred in 49/74 (indomethacin) v 52/74 (ibuprofen) (difference not significant). Urine output was assessed by bag urine collection and was significantly lower in the indomethacin group on days 3 to 7 after birth, during which time mean serum creatinine was also significantly higher in the indomethacin group. Oliguria (urine output 1 ml/kg/hour or less) occurred in 14 babies in the indomethacin group and five in the ibuprofen group. Necrotising enterocolitis occurred in eight (indomethacin) v four (ibuprofen) (not statistically significant) and babies with oliguria were significantly more likely to develop necrotising enterocolitis than those without oliguria.

In the accompanying editorial, it was pointed out that the babies in this trial were relatively mature (average 28 weeks) and the effectiveness of ibuprofen at lower gestational ages is uncertain. There is currently no suitable preparation of ibuprofen commercially available.

ARCHIVIST